We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$357M
Cap. Flow %
-3.72%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Miscellaneous 5.91%
3 Financials 0.34%
4 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTX
126
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$481K 0.01%
107,300
– –
ONC
127
BeOne Medicines Ltd
ONC
$39.2B
$385K ﹤0.01%
+12,925
New +$379K
ALIM
128
DELISTED
Alimera Sciences
ALIM
$308K ﹤0.01%
16,667
-83,333
-83% -$2.22M
ARLZ
129
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$225K ﹤0.01%
+68,143
New +$257K
ACAD icon
130
Acadia Pharmaceuticals
ACAD
$4.74B
– –
-1,401,600
Closed -$39.2M
CERS icon
131
Cerus
CERS
$514M
– –
-578,300
Closed -$3.43M
CYH icon
132
Community Health Systems
CYH
$412M
– –
-2,627,394
Closed -$40.2M
ENTA icon
133
Enanta Pharmaceuticals
ENTA
$377M
– –
-249,400
Closed -$7.33M
ENSG icon
134
The Ensign Group
ENSG
$10.1B
– –
-549,680
Closed -$11.6M
FATE icon
135
Fate Therapeutics
FATE
$277M
– –
-692,900
Closed -$1.25M
VTRS icon
136
Viatris
VTRS
$19.1B
– –
-69,800
Closed -$3.23M
MRTX
137
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-197,859
Closed -$4.23M
CLVS
138
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-660,900
Closed -$12.7M
SRRA
139
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-40,579
Closed -$10.9M
GWPH
140
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-190,600
Closed -$13.8M
PTLA
141
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-100,000
Closed -$2.04M
ACHN
142
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-200,000
Closed -$1.54M
TSRO
143
DELISTED
TESARO, Inc.
TSRO
– –
-1,912,000
Closed -$84.2M
CNXR
144
DELISTED
Connecture, Inc.
CNXR
– –
-1,740,000
Closed -$4.45M
XNPT
145
DELISTED
XENOPORT, INC.
XNPT
– –
-6,000,400
Closed -$27.1M
BITI
146
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-268,672
Closed -$7.09M
BXLT
147
DELISTED
BAXALTA INC COM STK (DE)
BXLT
– –
-326,000
Closed -$13.2M
QGENF
148
DELISTED
QIAGEN NV
QGENF
– –
-256,800
Closed -$5.74M
ANAC
149
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-53,300
Closed -$2.85M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed withdrew a net $357M in Q2 2016, closing 21 positions and reducing 32 holdings. Its most notable exit was Allergan plc, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Molina Healthcare worth $91.7M.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.